In a report released today, Gbola Amusa from Chardan Capital reiterated a Buy rating on Spring Bank Pharmaceuticals Inc (NASDAQ: SBPH), with a price target of $45. The company’s shares opened today at $13.
Amusa noted:
“We note that, although capsid inhibitors (CpAMs) have shown potentially greater reductions in HBV DNA [e.g., phase Ib data from Assembly Biosciences (Neutral)], we understand there has been no evidence of HBsAg reduction, which is considered a clinically meaningful metric of a functional cure. Safety for inarigivir continues to be a positive, with no SAEs and limited treatment- emergent adverse events (none above Grade 3).”
According to TipRanks.com, Amusa is a 5-star analyst with an average return of 25.8% and a 54.4% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
Currently, the analyst consensus on Spring Bank Pharmaceuticals Inc is a Moderate Buy with an average price target of $40, implying a 207.7% upside from current levels. In a report released today, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $35 price target.
.
See today’s analyst top recommended stocks >>
Based on Spring Bank Pharmaceuticals Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $4.86 million. In comparison, last year the company had a GAAP net loss of $8.89 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Spring Bank Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. Its pipeline include RIG-I & STING Agonists platforms. The company was founded by Douglas J. Jensen and Radhakrishnan P.
